



Institutional Biosafety Committee Meeting Minutes

The meeting was called to order on 10/28/2025 at 11:00AM. A quorum was present. The meeting was held via Zoom and in-person (Melville Library – 5th Floor, Room W5530). The meeting was open.

Attendance

Voting Members Present:

Dafang Wang
Hwan Kim
Jorge Escobar
Nicholas Carpino
Jeronimo Cello
Christopher Kuhlow

Non-Voting Attendees, Staff and Guests Present:

Rebecca Dahl
Lu-Ann Kozlowski
Terrence Rusch

Recording:

Erin Augello

Items

1. Meeting called to order at 11:00AM

2. Next meeting date and general announcements

The next meeting date is 11/25/2025. Dr. Carpino surveyed the assembled group to assess any conflict of interest or quorum issues. Members should recuse themselves and leave the room or Zoom meeting during the review of a study on which they have a conflict of interest.

3. Review of minutes from last meeting

Review type: Full Committee Review

Action: Approved

Effective date: 10/28/2025
Vote: Total = 6; For = 6; Opposed = 0; Abstained 0

4. Continuing reviews requiring IBC review

This section was reviewed and noted by the committee.

5. New studies for committee review

a. PROTO202500029 Notch responsive gene regulation

PI:	Julia Rogers
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: National Institutes of Health, Grant Office ID: FP00014168, Funding Source ID: R00GM144750
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	IIID
Containment Conditions:	BSL-2

Determination: Modifications Required

Modifications (If Applicable):

i. In Section: Biosafety Summary

Item 1. The PI describes use of murine stem cell virus retrovirus system (MigR1) and MMLV in other sections of the protocol. Therefore, select the “Viruses or Prions” option from the drop down menu and provide requested information on the new Viruses page.

ii. In Section: Biohazards

Item 1. MMLV and MSCV vectors should be listed here.

iii. In Section: Recombinant or Synthetic Nucleic Acid Usage

Item 1. III F does not apply. Please unselect Section III-F.

iv. In Section: Risk Group and Containment Practices

Item 1. MMLV and MSCV vectors are RG1 not RG2. Please change to RG1.

v. In Section: Exposure Assessment and Protective Equipment

Item 1. The parental MMLV- and MSCV-based vectors, when pseudo typed with VSV-G, produce infectious, replication-defective viral particles capable of transducing human cells, which carry a potential risk of insertional mutagenesis. The PI should acknowledge this possible consequence of exposure to these viral vectors. In addition, since the protocol involves the use of human cell lines, the PI should also address potential consequences in the event of exposure to bloodborne pathogens.

Effective Date: 10/30/2025

Project Expiration: 10/29/2026

Votes:

For:	6
Against:	0

Recused:	0
Absent:	2
Abstained:	0

b. PROTO202500035 Lentiviral Overexpression of MKK6 in RAW264.7 Macrophage Cells

PI:	Donghui Zhu
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: National Institute on Aging, Grant Office ID: 157611, Funding Source ID: AG064798
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	IIID
Containment Conditions:	BSL-2

Determination: Modifications Required**Modifications (If Applicable):**

i. In Section: Risk Group and Containment Practices

Item 1. Change to RG3 since lentivirus is derived from HIV.

Effective Date: 10/30/2025**Project Expiration:** 10/29/2026**Votes:**

For:	6
Against:	0
Recused:	0
Absent:	2
Abstained:	0

6. Amendments requiring IBC review

a. AMEND202500111 2025 Renewal

PI:	Robert Thacker
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	3D
Containment Conditions:	BSL-2

Determination: Approved**Modifications (If Applicable):****Effective Date:** 10/16/2025

Project Expiration: 10/15/2026

Votes:

For:	6
Against:	0
Recused:	0
Absent:	2
Abstained:	0

b. AMEND202500112 Personnel update for 971351

PI:	Dongyan Tan
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	3D
Containment Conditions:	BSL-2

Determination: Approved

Modifications (If Applicable):

Effective Date: 10/10/2025

Project Expiration: 10/09/2026

Votes:

For:	6
Against:	0
Recused:	0
Absent:	2
Abstained:	0

c. AMEND202500115 Update 214200 full review

PI:	Erwin London
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	3D
Containment Conditions:	BSL-2

Determination: Modifications Required

Modifications (If Applicable):

i. In Section: Biosafety Summary

Item 1. PI indicates use of lentivirus in rsNAM Work Description Section 1. Therefore, list lentivirus in the Table, provide the requested information, and select the “Viruses or Prions” option from the drop down menu and provide the requested information.

ii. In Section: Biohazards

Item 1. List lentivirus and provide requested information.

iii. In Section: Recombinant or Synthetic Nucleic Acid Usage

Item 1. Please indicate Section III-D, not III-F.

iv. In Section: Recombinant or Synthetic Nucleic Acid Work Description

Item 3. The PI’s response lists several reporter and cellular genes (GFP, luciferase, Notch, insulin receptor) but omits VSV-G and SARS-CoV-2 spike, which are also expressed as part of the pseudo-virus system. Both genes should be described here, including their species of origin and biological function.

v. In Section: Risk Group and Containment Practices

Item 1. Change to "RG3" since lentivirus is derived from HIV.

vi. In Section: Exposure Assessment and Protective Equipment

Item 1. The PI’s statement that “There should be no consequences. Nothing being used as infective.” is incorrect. The protocol involves use of lentiviral vectors, which are infectious though replication-defective and therefore capable of insertional mutagenesis in human cells.

Even with third-generation lentiviral systems, there remains a small but recognized risk of generating replication-competent lentivirus (RCL), which could potentially infect humans or animals. In addition, the protocol includes work with human cells, which carries a potential risk of exposure to bloodborne pathogens. The PI should revise this section to acknowledge these biosafety concerns and describe the possible consequences of accidental exposure or environmental release

Item 4. BSC certification date is incorrect. Please provide the accurate information for latest BSC certification date

Effective Date: 12/7/2025

Project Expiration: 12/6/2026

Votes:

For:	6
Against:	0
Recused:	0
Absent:	2
Abstained:	0

d. AMEND202500117 Continuing Review for Full Board

PI:	Charles Vorkas
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	3D

Containment Conditions:	BSL-2
-------------------------	-------

Determination: Modifications Required**Modifications (If Applicable):**

i. In Section: Protocol Team Members

Item 1. Is Nezar Mehanna still a Team Member. If not, please remove from list.

ii. In Section: Bacteria, Yeasts, Fungi, or Parasites

Item 2. Several microorganisms are listed here; however, the PI does not describe what experimental work will be performed with these agents. The current protocol appears to focus exclusively on Mycobacterium tuberculosis. The PI should clarify whether the additional microorganisms are used in the context of the M. tuberculosis studies (e.g., as controls, co-infections, or comparative models) or if they represent separate experiments. If these microorganisms are to be used in independent studies unrelated to M. tuberculosis, the PI needs to submit a separate IBC protocol describing those experiments.

iii. In Section: Biohazards

Item 1. If utilizing the microorganisms listed in Item 2 on the “Bacteria, Yeasts, Fungi or Parasites” page, then include them in the list of Biohazards on this page.

iv. In Section: Exposure Assessment and Protective Equipment

Item 1. The protocol involves the use of human cells; however, the PI does not address the potential consequences of exposure to bloodborne pathogens from human cells. Please address this.

Item 4. Please provide correct date of last BSC certification.

Effective Date: 10/14/2025

Project Expiration: 10/13/2026

Votes:

For:	6
Against:	0
Recused:	0
Absent:	2
Abstained:	0

7. Review of incidents

None

8. Review of other agenda items

None

9. Inspection results

All inspections and responses were summarized by Mr. Kuhlow and reviewed and noted by the committee.

10. Discussion items/readings (major and minor points of order)

None

11. Meeting adjourned at 12:02PM

